01
Entecavir 142217-69-4 anti-HBV
Product Specification
Appearance: | White or off-white powder |
Identification: | HPLC、IR |
water: | 6.0%~6.5% |
single impurity I: | ≤0.1% |
single impurity II: | ≤0.1% |
impurity I + impurity II: | ≤0.30% |
specific rotation: | +24°~ +28° |
heavy metal: | <20ppm |
methanol: | <0.3% |
Limit of bacterial: | NMT 1000cfu/g |
Limit of Mildew and microzyme: | NMT 100cfu/g |
Limit of Escherichia coli & mites: | Not allowed |
assay: | 98.5~101.0% |
description1
PRODUCT DESCRIPTION
Entecavir is a cyclopentyl guanosine analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection, and it is the third nucleoside or nucleotide analog to be marketed for this indication. Lamivudine, a deoxythiacytosine analog, and adefovir dipivoxil, a nucleotide analog, have been marketed since 1998 and 2002, respectively. Entecavir and adefovir are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections.
The most common side effects of entecavir: the increase of ALT, fatigue, dizziness, nausea, abdominal pain, abdominal discomfort, abdominal discomfort, liver, muscle, insomnia, rubella and indigestion, also be found in neutrophils decreased slightly.
These adverse reactions were mild to moderate. It also found that, as the same type of antiviral drugs, entecavir and the first generation of antiviral drugs have similar side effects, such as acid poisoning, hepatomegaly, liver fatty degeneration in the withdrawal will appear rebound phenomenon.
Entecavir is a new generation of guanine nucleoside analogues oral medicine for treatment of hepatitis B virus infection in, mainly for the treatment of adult patients with viral replication activity and serum transaminase continued to increase, or liver tissue for pathological activity of chronic hepatitis B, is currently down virus the fastest and the most powerful, the mutation rate lowest nucleoside analogues.